Amgen Rated Among High Yield Fortune 500 Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Yahoo Finance
- Dividend Yield: Amgen Inc. (NASDAQ:AMGN) boasts an annual dividend yield of 2.85%, placing it among the 12 High Yield Fortune 500 Stocks, indicating its stable cash flow and attractiveness for income-seeking investors.
- Price Target Increase: Morgan Stanley analyst Terence Flynn raised Amgen's price target from $322 to $340 while maintaining an 'Equal Weight' rating, suggesting a cautious outlook as the new target still indicates over 4% downside risk from current levels.
- Uplizna Approval: Amgen's Uplizna received FDA approval last year as the first treatment for Immunoglobulin G4-related disease (IgG4-RD), with additional approval for generalized myasthenia gravis (gMG) expected in February 2026, potentially opening new revenue streams for the company.
- Market Potential: Morgan Stanley noted a strong start for Uplizna in the gMG market, projecting that the market could double to over $10 billion in the next five years, highlighting Amgen's growth potential and competitive position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 354.060
Low
280.00
Averages
363.10
High
425.00
Current: 354.060
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen Rated Among High Yield Fortune 500 Stocks
- Dividend Yield: Amgen Inc. (NASDAQ:AMGN) boasts an annual dividend yield of 2.85%, placing it among the 12 High Yield Fortune 500 Stocks, indicating its stable cash flow and attractiveness for income-seeking investors.
- Price Target Increase: Morgan Stanley analyst Terence Flynn raised Amgen's price target from $322 to $340 while maintaining an 'Equal Weight' rating, suggesting a cautious outlook as the new target still indicates over 4% downside risk from current levels.
- Uplizna Approval: Amgen's Uplizna received FDA approval last year as the first treatment for Immunoglobulin G4-related disease (IgG4-RD), with additional approval for generalized myasthenia gravis (gMG) expected in February 2026, potentially opening new revenue streams for the company.
- Market Potential: Morgan Stanley noted a strong start for Uplizna in the gMG market, projecting that the market could double to over $10 billion in the next five years, highlighting Amgen's growth potential and competitive position in the biopharmaceutical sector.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Future Outlook for Obesity Medications
- Intensifying Market Competition: At the American Diabetes Association Scientific Sessions, Eli Lilly and Novo Nordisk showcased their new GLP-1 drugs, with Novo Nordisk's Wegovy pill achieving over 3 million prescriptions within five months of launch, indicating the potential of oral medications to attract more patients to weight-loss treatments.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data on their respective GLP-1 pills, which, if successful in Phase 3 trials, are expected to hit the market by 2029, further enriching the options available to meet the growing demand for obesity treatments.
- Innovative Treatment Frequency: Pfizer's drug, acquired through its $10 billion purchase of Metsera, shows potential for monthly injections, while Amgen is testing a drug that could be administered quarterly, significantly improving patient adherence and reducing the burden of weekly injections.
- Exploration of Emerging Therapies: Zealand Pharma's petrelintide drug demonstrated an average weight loss of nearly 11% in mid-stage trials, which, while less effective than existing medications, had fewer side effects, leading the CEO to believe that this could spark strong demand for new therapies and potentially reshape the obesity treatment market.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
AbbVie Expands Blood Cancer Treatment Market with New Data
- Market Expansion Potential: AbbVie showcased 21 research data points on blood cancers at the European Hematology Association Congress, covering various types including chronic lymphocytic leukemia, which could open new indications for existing drugs and drive future revenue growth.
- Revenue Diversification: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, highlighting its significance as a revenue source despite the focus on immunology, thereby supporting R&D and dividend payments.
- Risk Management Strategy: In response to the challenges posed by Humira's patent expiration, AbbVie has aggressively built new growth platforms across immunology, oncology, and neuroscience, reducing dependence on any single product and enhancing cash flow resilience.
- Clinical Trial Outlook: AbbVie continues to invest in expanding existing therapies into new indications and advancing next-generation blood cancer treatments, with successful clinical trials creating potential for new approvals, larger patient populations, and longer revenue runways, ensuring long-term cash flow to support dividend growth.
See More
Amgen Re-evaluates Tavneos Data Amid FDA Concerns
- FDA Safety Concerns: The FDA has proposed withdrawing Tavneos (avacopan) from the market due to safety issues, including 76 cases of serious drug-induced liver injury, which could significantly impact Amgen's market share and reputation.
- Independent Data Reevaluation: Amgen has engaged the Duke Clinical Research Institute to conduct an independent and fully blinded re-adjudication of primary endpoint results from the ADVOCATE study, demonstrating the company's commitment to data integrity and transparency in an effort to regain FDA trust.
- Regulatory Communication: An Amgen spokesperson stated that the company will carefully review the findings and maintain engagement with regulators, investigators, and the healthcare community, which may help alleviate market concerns regarding the safety of its drug.
- Market Reaction: This situation could lead to decreased investor confidence in Amgen, particularly as the FDA considers withdrawing the drug, potentially affecting future sales and R&D investment decisions.
See More
Amgen Rated Among High Yield Fortune 500 Stocks
- Dividend Yield: Amgen Inc. (NASDAQ:AMGN) boasts an annual dividend yield of 2.85%, placing it among the 12 High Yield Fortune 500 Stocks, indicating its stable cash flow and attractiveness for income-seeking investors.
- Price Target Increase: Morgan Stanley analyst Terence Flynn raised Amgen's price target from $322 to $340 while maintaining an 'Equal Weight' rating, suggesting a cautious outlook as the new target still indicates over 4% downside risk from current levels.
- Uplizna Approval: Amgen's Uplizna received FDA approval last year as the first treatment for Immunoglobulin G4-related disease (IgG4-RD), with additional approval for generalized myasthenia gravis (gMG) expected in February 2026, potentially opening new revenue streams for the company.
- Market Potential: Morgan Stanley noted a strong start for Uplizna in the gMG market, projecting that the market could double to over $10 billion in the next five years, highlighting Amgen's growth potential and competitive position in the biopharmaceutical sector.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Future Outlook for Obesity Medications
- Intensifying Market Competition: At the American Diabetes Association Scientific Sessions, Eli Lilly and Novo Nordisk showcased their new GLP-1 drugs, with Novo Nordisk's Wegovy pill achieving over 3 million prescriptions within five months of launch, indicating the potential of oral medications to attract more patients to weight-loss treatments.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data on their respective GLP-1 pills, which, if successful in Phase 3 trials, are expected to hit the market by 2029, further enriching the options available to meet the growing demand for obesity treatments.
- Innovative Treatment Frequency: Pfizer's drug, acquired through its $10 billion purchase of Metsera, shows potential for monthly injections, while Amgen is testing a drug that could be administered quarterly, significantly improving patient adherence and reducing the burden of weekly injections.
- Exploration of Emerging Therapies: Zealand Pharma's petrelintide drug demonstrated an average weight loss of nearly 11% in mid-stage trials, which, while less effective than existing medications, had fewer side effects, leading the CEO to believe that this could spark strong demand for new therapies and potentially reshape the obesity treatment market.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
AbbVie Expands Blood Cancer Treatment Market with New Data
- Market Expansion Potential: AbbVie showcased 21 research data points on blood cancers at the European Hematology Association Congress, covering various types including chronic lymphocytic leukemia, which could open new indications for existing drugs and drive future revenue growth.
- Revenue Diversification: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, highlighting its significance as a revenue source despite the focus on immunology, thereby supporting R&D and dividend payments.
- Risk Management Strategy: In response to the challenges posed by Humira's patent expiration, AbbVie has aggressively built new growth platforms across immunology, oncology, and neuroscience, reducing dependence on any single product and enhancing cash flow resilience.
- Clinical Trial Outlook: AbbVie continues to invest in expanding existing therapies into new indications and advancing next-generation blood cancer treatments, with successful clinical trials creating potential for new approvals, larger patient populations, and longer revenue runways, ensuring long-term cash flow to support dividend growth.
See More
Amgen Re-evaluates Tavneos Data Amid FDA Concerns
- FDA Safety Concerns: The FDA has proposed withdrawing Tavneos (avacopan) from the market due to safety issues, including 76 cases of serious drug-induced liver injury, which could significantly impact Amgen's market share and reputation.
- Independent Data Reevaluation: Amgen has engaged the Duke Clinical Research Institute to conduct an independent and fully blinded re-adjudication of primary endpoint results from the ADVOCATE study, demonstrating the company's commitment to data integrity and transparency in an effort to regain FDA trust.
- Regulatory Communication: An Amgen spokesperson stated that the company will carefully review the findings and maintain engagement with regulators, investigators, and the healthcare community, which may help alleviate market concerns regarding the safety of its drug.
- Market Reaction: This situation could lead to decreased investor confidence in Amgen, particularly as the FDA considers withdrawing the drug, potentially affecting future sales and R&D investment decisions.
See More
